In connection with the new facility, the Company’s Board of Directors authorized an increase to its share repurchase program from $100 million to $300 million. As of March 18, 2026, the Company has repurchased approximately $38 million of common stock under the prior and existing share repurchase program at an average price of $28.98 per share.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX:
- TG Therapeutics announces publication of data from studies on Briumvi
- TG Therapeutics Earnings Call Highlights BRIUMVI Surge
- Precision to get $7.5M in proceeds from TG Therapeutics for azer-cel milestone
- TG Therapeutics Confronts Rising AI Regulatory and IP Risks That Could Pressure Costs, Strategy, and Growth
- Buy Rating Backed by Briumvi’s Strong Commercial Ramp, Growing CD20 Market Share, and Visible Long‑Term Revenue Expansion